SPS
ANIK icon

Susquehanna Portfolio Strategies’s Anika Therapeutics ANIK Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-30,976
Closed -$765K – 39
2024
Q3 		$765K Hold
30,976
– – 0.05% 217
2024
Q2 		$785K Sell
30,976
-700
-2% -$18.1K 0.03% 317
2024
Q1 		$805K Hold
31,676
– – 0.02% 501
2023
Q4 		$718K Buy
+31,676
New +$655K 0.01% 681

Other funds holding ANIK

TI
Trigran Investments Northbrook, Illinois $418M AUM 3.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AFA
Alta Fundamental Advisers New York $265M AUM 98.61% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return

Susquehanna Portfolio Strategies's ANIK Position: Q4 2024 in Review

Susquehanna Portfolio Strategies sold out of Anika Therapeutics (ANIK) in Q4 2024, closing a stake of 30,976 shares — an estimated $765K sold.

Susquehanna Portfolio Strategies first reported a position in ANIK in Q4 2023 and held it in 4 quarters. The position peaked at $805K in Q1 2024. 109 funds tracked by Wall St. Rank hold ANIK as of Q4 2024.

  • Susquehanna Portfolio Strategies reported no remaining Anika Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Susquehanna Portfolio Strategies sold 30,976 Anika Therapeutics shares in Q4 2024, an estimated $765K.
  • Susquehanna Portfolio Strategies first reported a position in Anika Therapeutics in Q4 2023 and held it in 4 quarters.
  • Susquehanna Portfolio Strategies's Anika Therapeutics position peaked at $805K in Q1 2024.
  • 109 funds tracked by Wall St. Rank held Anika Therapeutics as of Q4 2024.

Based on Susquehanna Portfolio Strategies's 13F filing for Q4 2024, filed 14 Feb 2025.